Renin–angiotensin system inhibitors, the mainstay for treating CKD, are unhelpful to stop its progression toward end-stage renal disease (de Zeeuw, 2011); moreover, they might cause many adverse effects (Budde et al., 2007; Fu-de, 2015). This evidence concerns the gene REN and chronic kidney disease.